Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia

Schreiner, Andreas; Aadamsoo, Kaire; Altamura, A.; Franco, Manuel; Gorwood, Philip; Neznanov, Nikolaj; SCHRONEN, Juan; Ucok, Vehbi; ZINK, Mathias; JANIK, Adam; CHERUBIN, Pierre; LAHAYE, Marjolein; HARGARTER, Ludger

doi:10.1016/j.schres.2015.08.015

Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia

Atıf İçin Kopyala

Schreiner A., Aadamsoo K., Altamura A. C., Franco M., Gorwood P., Neznanov N. G., ...Daha Fazla

SCHIZOPHRENIA RESEARCH, cilt.169, ss.393-399, 2015 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 169
Basım Tarihi: 2015
Doi Numarası: 10.1016/j.schres.2015.08.015
Dergi Adı: SCHIZOPHRENIA RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
Sayfa Sayıları: ss.393-399
İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Relapse and acute exacerbation are common in schizophrenia and may impact treatment response and outcome. Evidence is conflicting in respect to superiority of long-acting injectable antipsychotic therapies versus oral antipsychotics in relapse prevention. This randomized controlled study assessed the efficacy of paliperidone palmitate versus oral antipsychotics for relapse prevention.